• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New Canadian Report Shows Positivity Instead of Criticism is Key in Diabetes Management

    10/30/24 9:50:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABT alert in real time by email
    • Canadians living with type 2 diabetes agree that uplifting words, positive feedback and supportive tools are the most powerful motivators

    MISSISSAUGA, ON, Oct. 30, 2024 /CNW/ -- Abbott (NYSE:ABT) today released new data highlighting the emotional challenges faced by people living with type 2 diabetes, revealing key motivators to help them manage their condition.

    New Canadian Report Shows Positivity Instead of Criticism is Key in Diabetes Management

    Nearly 12 million Canadians are living with diabetes or pre-diabetes, and the overwhelming majority have or will be diagnosed with type 2.1 While a variety of factors contribute to the risk of developing type 2 diabetes, it is often positioned to be in someone's control and associated with lifestyle factors, like nutrition and exercise.2 This perception, along with the words and actions of others, can have a profound impact on those navigating the realities of type 2 diabetes.

    Abbott's FreeStyle Libre Report: The Power of Positive Motivation for Type 2 Diabetes Management explores the experiences of Canadians with type 2 diabetes and the factors influencing their care. It includes expert recommendations on how those living with the condition, their loved ones, healthcare teams, and government and community leaders can offer support with encouragement and empathy.

    Results from the report found that:

    • Type 2 diabetes comes with many emotions, with Canadians saying their diabetes makes them feel stressed (25 per cent) and anxious (21 per cent).3
    • Positivity is key: Canadians agree that positive reinforcement from their healthcare providers (80 per cent) and friends and family (67 per cent) help them better manage their diabetes.4
    • Professional advice is welcomed, noting that two in five Canadians (41 per cent) appreciate guidance and direction from their healthcare providers.
    • Data supports motivation, with users of sensor-based glucose monitors, like Abbott's FreeStyle Libre systems, saying the information offered by these tools helps them understand how lifestyle choices affect their diabetes (82 per cent) and helps keep them motivated to better manage their condition (77 per cent).5

    "When it comes to diabetes management, we know there is power in encouragement," says Dr. Michael Vallis, a health psychologist specializing in motivation and psychosocial adaptation to chronic conditions, including diabetes. "Our supportive words, paired with the real-time feedback offered by tools like flash glucose monitoring systems, can give our loved ones a boost and help them feel like their diabetes goals are achievable."

    The report features recommendations from diabetes experts, including Dr. Vallis on helping to manage the diabetes experience for Canadians. Their recommendations include listening empathetically, leading with positivity and using supportive diabetes tools like Abbott's FreeStyle Libre 2* system, which can help people understand their health journey by giving them real-time feedback on their progress. Additionally, they offer tips to help those with diabetes stay motivated.

    "Abbott is dedicated to making a positive impact on the lives of people living with diabetes," said Luz Herrera, general manager of Abbott's diabetes care business in Canada. "By highlighting the experiences of those with type 2 diabetes and providing effective solutions, we strive to enhance the health and wellbeing of millions across the country who are on their journey to better health. "

    Learn more about the report at myfreestyle.ca.

    About the Report:

    Abbott's FreeStyle Libre Report explores the perspectives of Canadians living with type 2 diabetes and the role of motivation in their diabetes management and overall experience.

    The report pulls data from an online survey conducted by Leger Marketing, on behalf of Abbott, between May 23 and May 30, 2024. The survey was made up of 307 Canadian respondents, 18 years and older, living with type 2 diabetes, and a probability sample would have a margin of error of ±5.6%, 19 times out of 20. The sample was designed to ensure the respondent population accurately reflects the diversity of each region, gender, age, ethnicity and language in Canada.

    About Abbott:

    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

    Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    DISCLAIMERS

    * The FreeStyle Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. Always read and follow the label/insert.

    1 Diabetes Canada. "Diabetes in Canada," Diabetes.ca. 2023. https://www.diabetes.ca/advocacy---policies/advocacy-reports/national-and-provincial-backgrounders/diabetes-in-canada.

    2 Diabetes Canada. "'Causes' of diabetes," Diabetes.ca. 2023. https://www.diabetes.ca/about-diabetes-(3)/causes-of-diabetes.

    3 Leger Marketing. Abbott Diabetes Care: Type 2 Diabetes, Q6. June 2024.

    4 Leger Marketing. Abbott Diabetes Care: Type 2 Diabetes, Q11. June 2024.

    5 Leger Marketing. Abbott Diabetes Care: Type 2 Diabetes, Q12. June 2024.

    New Canadian Report Shows Positivity Instead of Criticism is Key in Diabetes Management

    Abbott Logo

    SOURCE Abbott

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2024/30/c5454.html

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What do Canadians with type 2 diabetes identify as important motivators in managing their condition?

      Canadians living with type 2 diabetes find that supportive words and positive feedback are key motivators for managing their condition.

    • What percentage of Canadians with diabetes believe that positive reinforcement from healthcare providers is helpful?

      The report revealed that 80% of Canadians prefer positive reinforcement from healthcare providers to manage their diabetes.

    • What emotional challenges do Canadians living with type 2 diabetes report?

      The survey found that 25% of Canadians feel stressed and 21% feel anxious due to their diabetes.

    • How do sensor-based glucose monitors assist Canadians with diabetes?

      Using glucose monitoring tools helps 82% of users understand how their lifestyle choices affect diabetes management.

    • What strategies do diabetes experts recommend for supporting individuals with type 2 diabetes?

      Recommendations include empathetic listening, leading with positivity, and using supportive tools like the FreeStyle Libre system.

    Recent Analyst Ratings for
    $ABT

    DatePrice TargetRatingAnalyst
    10/10/2025$145.00Buy
    The Benchmark Company
    7/18/2025$145.00Hold → Buy
    Jefferies
    6/16/2025$143.00Market Perform
    Leerink Partners
    10/8/2024$130.00Outperform
    Oppenheimer
    9/19/2024$131.00Overweight
    Piper Sandler
    7/30/2024Buy → Hold
    Edward Jones
    5/30/2024$121.00Buy
    Goldman
    7/21/2023Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $ABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Stratton John G

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/2/26 5:31:52 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Roman Michael F

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/2/26 5:24:18 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Gonzalez Patricia Paola

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/2/26 5:15:44 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    SEC Filings

    View All

    SEC Form S-8 filed by Abbott Laboratories

    S-8 - ABBOTT LABORATORIES (0000001800) (Filer)

    3/23/26 5:30:42 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Laboratories filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    3/23/26 8:54:17 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Abbott Laboratories

    DEFA14A - ABBOTT LABORATORIES (0000001800) (Filer)

    3/13/26 4:01:21 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ABT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health

    With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthyABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE:ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing tension: 74% of U.S. adults believe most chronic diseases, such as diabetes or cardiovascular disease, are preventable, but only 1 in 4 feel very confident in knowing how to care for their health. In the U.S. alone, three in four American adults have at least one chronic condition1. With chronic disease continually on the rise2

    4/9/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

    Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisionsAllows oncologists to order tests and view results directly in the clinical workflowABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform. Through this integration, onc

    3/30/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott hosts conference call for first-quarter earnings

    ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical

    3/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott Labs upgraded by Jefferies with a new price target

    Jefferies upgraded Abbott Labs from Hold to Buy and set a new price target of $145.00

    7/18/25 7:54:43 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Abbott Labs with a new price target

    Leerink Partners initiated coverage of Abbott Labs with a rating of Market Perform and set a new price target of $143.00

    6/16/25 8:17:39 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Leadership Updates

    Live Leadership Updates

    View All

    Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"

    Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin "The More the Merrier" is the first Hallmark movie ever to include cameos from real-life individuals who have overcome cardiovascular challengesCharacter in the movie was inspired by Abbott HeartMates member Zeke Mankins, who has established a friendship with Hamlin through Hamlin's ambassador role for the HeartMates communityMovie premieres on Hallmark Channel on Nov. 28, 2025, during Hallmark's Merry Thanksgiving Weekend during "Countdown to Christmas"ABBOTT PARK, Ill., Nov. 4,

    11/4/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

    This summer, Abbott and Real Madrid are hosting tryouts across the U.S. to form the 'Abbott Dream Team'Tryout attendees will learn about health and sports nutrition, encouraging them to promote healthy habits and an active lifestyle in their communitiesEleven selected players will travel to Madrid, train at Real Madrid's world-class facilities, and be instructed by Real Madrid coachesAmerican soccer icon Clint Dempsey will mentor the athletes throughout their journeyABBOTT PARK, Ill., May 7, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the creation of the inaugural 'Abbott Dream Team.' The program will seek out talented soccer players from across the United States and give them a o

    5/7/25 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

    Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

    3/4/25 11:38:00 AM ET
    $ABT
    $TFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABT
    Financials

    Live finance-specific insights

    View All

    Abbott hosts conference call for first-quarter earnings

    ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical

    3/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott completes acquisition of Exact Sciences

    Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segmentsAdvances Abbott's mission to make healthcare more accessible and give people more control over their healthABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. "Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized trea

    3/23/26 8:50:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott declares 409th consecutive quarterly dividend

    ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 409th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio o

    2/20/26 11:38:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/13/24 4:55:58 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/23 10:54:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

    SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)

    2/9/22 3:15:56 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care